Curodont Repair is revolutionising dentistry

Prevention has always been at the heart of vVARDIS’s philosophy. How are your latest products helping to shift dentistry further towards prevention rather than restoration?
Dr Haley Abivardi: Curodont Repair is our hero product. It’s the first medication that can treat early decay. It’s more than prevention; it’s restoration, where the tooth makes its own filling. Approximately 80 % of patients sitting in the dental chair have early decay. Even as dental students, we learned that early decay had no treatment; we’d simply have to watch it and hope the patient returned in time. Drilling takes away too much healthy tooth structure. Dentists have always felt uneasy about this. Now, dentists or dental hygienists can treat early cavities in 5 minutes, freeing up chair time. It’s a win–win for everyone!

Dr Goly Abivardi: It is the first product to enable regeneration of enamel, and this is revolutionary! It allows dentists to treat early signs of cavities non-invasively. In medicine, we’ve done this for years—treating early signs of disease immediately—but in dentistry, this wasn’t possible until now. We’re introducing a new era in dentistry. For us, prevention, early intervention and accessibility have always been the focus. We believe that our product will have a great impact on patients and dentists. As dental professionals, we want the best for our patients.

We have over 25 years of scientific research behind this technology. Over the last decade, hundreds of thousands of patients have been treated successfully in the US and Europe—with no side effects. Universities are now including this technology in their curricula. It’s becoming the new standard of care—a completely new category.

Existing products act super ficially. Our product penetrates deeply into lesions, building a matrix that attracts minerals from the saliva so that calcium and phosphate can be crystalised into hydroxyapatite. The tooth effectively builds its own filling from minerals in the saliva. It’s biomimetic technology, harnessing natural
processes.

Dr Haley Abivardi: We’re achieving what was considered impossible: regenerating enamel. The tooth is restored to its natural state.

Dr Goly Abivardi: It’s beneficial for everyone. Patients appreciate non-invasive treatment; dentists see improved patient retention. Additionally, it generates new revenue for dental practices.

Since the last IDS, vVARDIS has partnered with OrbiMed to secure substantial financing. What impact has this partnership had on your strategic direction?
Dr Haley Abivardi: OrbiMed is highly respected in pharma, investing exclusively in world-class healthcare companies that address unmet medical needs. It’s the first time that it has invested in dentistry, because our product addresses the world’s leading non-communicable disease.

How have dental professionals’ attitudes towards non-invasive treatments changed over recent years, particularly since you introduced your technology?
Dr Goly Abivardi: Dentistry is shifting towards prevention and noninvasive approaches, making this the perfect time for Curodont. Patients too now understand the importance of early intervention.

Dr Haley Abivardi: Awareness of the link between oral and overall health has increased significantly. A few years ago, the World Health Organization passed a resolution recognising oral health as integral to general health, emphasising the mouth as the gateway to the body.

What’s your vision for the future of non-invasive dentistry?
Dr Haley Abivardi: Our goal is to make Curodont accessible to everyone everywhere. In the US, we introduced it early last year, and Curodont is already in nearly 10% of dental offices in the country. It’s rapidly growing. We are seeing a very high acceptance rate among patients. Our product is available already in the US, Europe and in the Emirates.

Tags: